EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms

Matthias Christen iD, Domenic Kaderli, Milos Ratknic, Adrián Dante de Angelis, Philipp Stefan Aebi iD, Naomi Porret iD, Joëlle Tchinda, Natalia Baran iD, Wuddri Rim, Pascale Julia Tanner, Sebastian Mathes iD, Anne Angelillo-Scherrer iD und 2 weitere

Journal of Clinical Medicine · 24.12.2025 · 15 (1) · 128

DOI: 10.3390/jcm15010128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.12.2025. Verfasst von Matthias Christen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ropeginterferon alfa-2b (Ropeg-IFNa) is increasingly used in myeloproliferative neoplasms (MPN), particularly polycythemia vera, but real-world data across subtypes are limited. We evaluated clinical and molecular responses to Ropeg-IFNa in routine practice.

Methods

We retrospectively analyzed 20 JAK2V617F-positive MPN patients treated at a tertiary center. Baseline features, dosing, treatment line, hematologic responses, adverse events, and serial JAK2V617F variant allele frequency (VAF) were extracted from records.

Results

Median age at initiation was 53 years; 55% were ELN high-risk. Ropeg-IFNa was started first-line or after peginterferon alfa-2a, hydroxyurea, or a tapered JAK2 inhibitor. Mean treatment duration was 14 ± 11 months at 195 ± 143 µg Q2W. Hematologic control increased from 45% at the start to 60% at the last follow-up. Among patients with serial molecular monitoring (n = 11), median JAK2V617F VAF declined from 21.2 to 12.7%. Ropeg-IFNa was generally well tolerated; adverse effects were mostly manageable, although 3/20 (15%) discontinued due to side effects, including mood disturbances, while others continued with supportive care and dose adjustments.

Conclusions

In this single-center cohort, Ropeg-IFNa was tolerable and associated with improved hematologic control and modest VAF reductions, supporting its use in multi-subtype MPN cohorts. These findings underscore the value of longitudinal driver-mutation monitoring during therapy.

Schlagwörter

Stichwörter der Autor:innen

JAK2 V617FMPN-Uessential thrombocytopeniapegylated interferon alphapolycythemia veraprimary myelofibrosis

Autor:innen und Institutionen

  • Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Department of Biomedical Research, University of Bern, 3008 Bern, Switzerland.

ORCID-Profile: Matthias Christen, Philipp Stefan Aebi, Naomi Porret, Natalia Baran, Sebastian Mathes, Anne Angelillo-Scherrer, Alicia Rovó, Sara C Meyer

Förderung

  • Swiss National Science Foundation

Zitieren

APA

Christen, M., Kaderli, D., Ratknic, M., de Angelis, A. D., Aebi, P. S., Porret, N., Tchinda, J., Baran, N., Rim, W., Tanner, P. J., Mathes, S., Angelillo-Scherrer, A., Rovó, A., & Meyer, S. C. (2025). Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms. Journal of Clinical Medicine, 15(1), 128. https://doi.org/10.3390/jcm15010128

Vancouver

Christen M, Kaderli D, Ratknic M, de Angelis AD, Aebi PS, Porret N, et al. Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms. Journal of Clinical Medicine. 2025;15(1):128. doi:10.3390/jcm15010128

BibTeX
@article{Christen2025,
  author = {Christen, Matthias and Kaderli, Domenic and Ratknic, Milos and de Angelis, Adrián Dante and Aebi, Philipp Stefan and Porret, Naomi and Tchinda, Joëlle and Baran, Natalia and Rim, Wuddri and Tanner, Pascale Julia and Mathes, Sebastian and Angelillo-Scherrer, Anne and Rovó, Alicia and Meyer, Sara C},
  title = {Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {128},
  doi = {10.3390/jcm15010128}
}
Kostenlos starten →